Skip to main content

Table 7 Comparison of medical costs of BT-naïve patients between the persistent (P) and non-persistent (NP) group

From: Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database

 

ADL

IFX

UST

Total

 

P

NP

Δ

P

NP

Δ

P

NP

Δ

P

NP

Δ

Number of patients

4

10

 

6

13

 

23

7

 

33

31

 

Cost (pre)

¥360

¥367

¥7

¥1062

¥848

- ¥214

¥597

¥621

¥24

¥653

¥629

- ¥24

In 1000

JPY unit

IP

¥0

¥0

¥0

¥603

¥249

- ¥354

¥201

¥36

- ¥165

¥250

¥122

- ¥128

OP

¥263

¥81

- ¥182

¥398

¥198

- ¥200

¥211

¥232

¥21

¥251

¥166

- ¥85

RX

¥97

¥286

¥189

¥61

¥401

¥340

¥186

¥353

¥167

¥152

¥341

¥189

Cost (increase)

¥2433

¥1621

- ¥812

¥2246

¥2608

¥362

¥2211

¥2254

¥43

¥2244

¥2126

-¥118

In 1000

JPY unit

IP

¥0

¥204

¥204

-¥174

¥1005

¥1179

-¥98

¥414

¥512

-¥100

¥577

¥677

OP

¥2460

¥946

- ¥1514

¥2446

¥1756

-¥690

¥2380

¥2021

-¥359

¥2402

¥1499

-¥903

RX

-¥27

¥471

¥498

-¥26

-¥153

-¥127

-¥71

-¥180

-¥109

-¥57

¥50

¥107

  1. P persistent, NP non-persistent, Δ costs of NP minus costs of P, ADL Adalimumab, IFX Infliximab, UST Ustekinumab, pre:12 months pre-initiation, increase: increase from pre to post 12 months post-initiation, JPY Japanese Yen, IP inpatient medical costs, OP outpatient medical cost, RX costs of drugs other than BTs